Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
French drugmaker Sanofi SA and Britain’s GlaxoSmithKline plan to create 200 million doses of the COVID-19 vaccine candidate accessible to the vaccine allocation program co-led by GAVI and the World Health Organization.
The companies said on October 28 they have signed a statement of intent with vaccine alliance GAVI, which is coordinating the global plan called COVAX.
COVAX aims to deliver 2 billion vaccine doses around the world at the end of 2021, and more than 180 countries have joined the plan.
The United States and UK are leading a hurry to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines.
GSK-Sanofi has signed a $2.1 billion deal with the US to provide it with over 100 million doses of its coronavirus vaccine candidate. The firms also have deals with the European Union and UK.
The initial results from an early mid-stage study of this Sanofi-GSK vaccine are expected in early December 2020, and the companies plan to file for regulatory approval in 2021.
The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines. It’ll be combined with an adjuvant, a substance that acts as a booster to the vaccine, made by GSK.
